

Likun Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2886861/publications.pdf>

Version: 2024-02-01

17
papers

789
citations

759233

12
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

1671
citing authors

#	ARTICLE	IF	CITATIONS
1	PARP Inhibition Suppresses GR β -MYCN β -CDK5 β -RB1 β -E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6839-6851.	7.0	50
2	Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. <i>International Journal of Cancer</i> , 2018, 142, 2163-2174.	5.1	39
3	Targeting the MYCN β -PARP β -DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 696-707.	7.0	80
4	N-MYC regulation of DNA damage response in neuroendocrine prostate cancer: mechanistic insight and novel combination therapy approaches. <i>Oncoscience</i> , 2018, 5, 273-275.	2.2	4
5	Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. <i>Cell Reports</i> , 2017, 18, 1970-1981.	6.4	83
6	Androgen receptor inhibitor-induced β -BRCAness β and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. <i>Science Signaling</i> , 2017, 10, .	3.6	200
7	Connecting androgen receptor signaling and the DNA damage response: Development of new therapies for advanced prostate cancer. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1321167.	0.7	7
8	Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness. <i>Oncotarget</i> , 2017, 8, 93315-93316.	1.8	8
9	Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. <i>Current Medicinal Chemistry</i> , 2017, 24, 1586-1606.	2.4	89
10	Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 46321-46334.	1.8	22
11	GLIPR1- β synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. <i>Molecular Cancer</i> , 2015, 14, 122.	19.2	24
12	Targeting Poly(ADP-Ribose) Polymerase and the c-Myb β -Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer. <i>Science Signaling</i> , 2014, 7, ra47.	3.6	73
13	Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance. <i>Asian Journal of Urology</i> , 2014, 1, 30-39.	1.2	1
14	New targets for resistant prostate cancer. <i>Oncotarget</i> , 2014, 5, 8816-8817.	1.8	6
15	Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70 β -mediated suppression of AURKA and TPX2. <i>Molecular Oncology</i> , 2013, 7, 484-496.	4.6	32
16	GLIPR1 Suppresses Prostate Cancer Development through Targeted Oncoprotein Destruction. <i>Cancer Research</i> , 2011, 71, 7694-7704.	0.9	31
17	Caveolin-1 Promotes Autoregulatory, Akt-Mediated Induction of Cancer-Promoting Growth Factors in Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2009, 7, 1781-1791.	3.4	40